← brief for 2026-09-01 · Slowing decline

Long-term outcome of pediatric anti-complement factor H antibody-associated atypical hemolytic uremic syndrome receiving abbreviated plasma exchange: a retrospective study from a single center.

Key takeaways

Children under 12 with a rare disease that clots the small blood vessels in the kidneys (atypical hemolytic uremic syndrome, caused by an antibody against a blood protein called factor H) were treated with a shortened course of plasma exchange, which washes the harmful antibody out of the blood, plus drugs that quiet the immune system. The center used this approach because the standard drug, eculizumab, was hard to get. Researchers looked back through old records at one hospital to see how these children did over the following years. Looking back at records can show a link between the treatment and the outcome, but it cannot prove the treatment caused it.

Who did this work

Vallabhaneni P · Dawman L · Rawat A · Nada R · Bhatia P · Singh T · Sekar A · Tiewsoh K

Source

Article · PubMed, Reducing protein and albumin in urine · 2026 Sep 1
https://pubmed.ncbi.nlm.nih.gov/42678244/